C1ORF106, recently named INAVA (Innate Immune Activator), was identified as a risk factor for the chronic inflammatory bowel diseases (IBD) by genome-wide association studies and targeted exome sequencing (Rivas et al., 2011). The gene discussed is INAVA; the disease is inflammatory bowel disease.